US Top Rating Updates on 12/13: PFE, EBAY, PINS, HZNP and More

Goldman Sachs analyst Chris Shibutani upgraded $Pfizer (PFE.US)$ to Buy from Neutral with a price target of $60, up from $47. Positive updates from the company's pipeline, and the potential for outperformance from the commercial new product launch portfolio over the course of the coming year, can drive "meaningful upside" to the value ascribed to Pfizer's base business, Shibutani tells investors in a research note.

Piper Sandler analyst Thomas Champion upgraded $Pinterest (PINS.US)$ to Overweight from Neutral with a price target of $30, up from $25. The analyst sees "multiple tailwinds" for the company into 2023 after his advertising buyer survey pointed to an improved ad product and rising market rising.

Keefe Bruyette analyst David Konrad upgraded $U.S. Bancorp (USB.US)$ to Outperform from Market Perform with a price target of $58, up from $52. The shares are trading at a "deep discount to historical valuations" with the market underestimating the earnings power of Union Bank given higher rates since the deal was announced, Konrad tells investors in a research note.